Illumina's 21 Percent Increase in Q3 Revenue Driven by MiSeq, HiSeq 2500, Sequencing Services | GenomeWeb

This article was originally published Oct. 26.

Due to continued growth in MiSeq sales, more customers than expected ordering upgrades to the HiSeq 2500, and a 54 percent uptick in its services business, Illumina's revenues rose 21 percent in the third quarter of 2012, to $285.9 million from $235.5 million in the third quarter of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.